<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chemotherapeutic agents used in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> are frequently associated with severe adverse reactions that compromise the efficacy of treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Predicting toxicity could enable therapy to be tailored </plain></SENT>
<SENT sid="2" pm="."><plain>Genetic variations have been associated with toxicity in patients treated with fluoropyrimidines (<z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, <z:chebi fb="0" ids="31348">capecitabine</z:chebi> and tegafur), <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, irinotecan and cetuximab </plain></SENT>
<SENT sid="3" pm="."><plain>Complexity of treatment and variability in toxicity classifications make it difficult to compare studies </plain></SENT>
<SENT sid="4" pm="."><plain>This article analyzes the association between toxicity and polymorphisms in DPYD, TYMS, MTHFR, ABCB1, UGT1A1, ERCC1, ERCC2, XRCC1, GSTT1 and GSTM1 </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the state-of-the-art and future perspectives are discussed </plain></SENT>
</text></document>